ProCE Banner Activity

Treatment Options for the Common Targetable Biomarkers for Advanced NSCLC: EGFR, KRAS, and HER2

Slideset Download
Download these slides from a live webinar for a review of recent data on treatment selection for patients with EGFR, KRAS, or HER2-positive NSCLC.

Released: June 05, 2022

Expiration: June 04, 2023

Share

Faculty

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck KGA, Mirati, Seattle Genetics, Takeda, and Tesaro and funds for research support paid to her institution from Blueprint, Calithera, Daiichi Sankyo, Elevation Oncology, Genentech, and Janssen.